So the key catalyst will be the P3 OA top line readout, potentially around October 2024, and only if the FDA allow us to up the dose to 2mg/kg, making the meeting with the FDA another key catalyst. It is possible regional deals could be struck prior to this readout given that potential partners may want to lock in a deal beforehand or risk having to pay more if the top line readout is a smashing success. PAR should have enough data to secure an upfront payment prior to the top line readout.
Ann: PAR Successful Placement and Fully Underwritten ANREO, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.020(4.76%) |
Mkt cap ! $174.8M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.0¢ | 42.0¢ | $347.2K | 796.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16968 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 2449 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |